Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

Summary

The purpose of this study is to evaluate the safety and effectiveness of treatment with branebrutinib treatment in participants with active systemic Lupus Erythematosus (SLE) or Primary Sjögren's Syndrome (pSS), or branebrutinib treatment followed by open-label abatacept treatment in study participants with active Rheumatoid Arthritis (RA).

Timeline

Start

2020-01-07

Primary completion

2022-12-05

Completion

2022-12-05

Publications

• Ostergaard M, Haavardsholm EA, Nowak M, Luo Y, Landis J, Fura A, Pachai C, Rotich D, Wang-Fischer Y, Carayannopoulos LN, Zammit D, Karabeber H, Wang A, Grasela DM. Efficacy and safety of branebrutinib (BMS-986195), an irreversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2a, randomised, double-blind, placebo-controlled study. Lancet Rheumatol. 2026 Jul;8(7):e539-e549. doi: 10.1016/S2665-9913(25)00374-1. Epub 2026 May 1.

Drugs

Indications